Corcept Therapeutics' ALS drug fails in mid-stage trial-February 2024-www.financetom.com

Corcept Therapeutics' ALS drug fails in mid-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Corcept Therapeutics' ALS drug fails in mid-stage trial

Dec 11, 2024 1:49 PM

Dec 11 (Reuters) - Corcept Therapeutics ( CORT ) said on

Wednesday its experimental drug failed to meet the main goal of

a mid-stage trial in patients with amyotrophic lateral

sclerosis, a fatal neurodegenerative disease.

Previous page： DXC Technology forecasts Q2 revenue above estimates on demand for cloud services Next page： Expedia beats second-quarter profit estimates on sustained international travel demand

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

DXC Technology forecasts Q2 revenue above estimates on demand for cloud services

Aug 8, 2024

Aug 8 (Reuters) - DXC Technology ( DXC ) forecast second-quarter revenue above Wall Street estimates on Thursday, driven by steady demand for its cloud-based services from businesses looking to incorporate AI features. Shares of the Tysons, Virginia-based company rose 7% in extended trading after DXC also raised its annual forecast for revenue. DXC now expects 2025 revenue in the...

Expedia beats second-quarter profit estimates on sustained international travel demand

Aug 8, 2024

(Reuters) - Online travel agency Expedia ( EXPE ) beat analysts' expectations on Thursday for second-quarter profit, helped by sustained demand for international travel, sending its shares up 7% after the bell. The travel environment was healthy in the second quarter and like the last few quarters, we saw strong ongoing demand internationally relative to the US, CEO Ariane Gorin...

Brazil bourse operator B3 recurring profit rises 5% in Q2

Aug 8, 2024

Aug 8 (Reuters) - Brazilian financial exchange operator B3 posted on Thursday a recurring net profit of 1.23 billion reais ($221.73 million) in the second quarter, up 5% from a year earlier. The result was slightly above analysts' expectations of a 1.17 billion reais recurring profit. ($1 = 5.5473 reais) ...

Moody's downgrades Intel's senior unsecured notes rating

Aug 8, 2024

Aug 8 (Reuters) - Moody's on Thursday downgraded chipmaker Intel's ( INTC ) senior unsecured rating to BAA1. (Reporting by Arsheeya Bajwa in Bengaluru; Editing by Anil D'Silva) ...